A Phase 2 Randomized, Open-label Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With the Capsid Inhibitor Lenacapavir as Long-Acting Treatment Dosed Every 6 Months in Virologically Suppressed Adults With HIV-1 Infection

  • McMahon, James (Primary Chief Investigator (PCI))
  • Roney, Janine (Project Manager)

Project: Research

Project Details

Effective start/end date13/07/2312/07/25


  • Clinical Trials
  • HIV-1